Baird raised the firm’s price target on Inari Medical (NARI) to $67 from $66 and keeps an Outperform rating on the shares. The firm estimates the company delivered mid-to-high-teens US VTE growth, which suggests the company is holding share better than some expected and Baird continues to argue for more sustainable multiple expansion as “bearish” debates seem to hold less ground.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NARI:
- Inari Medical price target raised to $52 from $50 at Piper Sandler
- Inari Medical raises FY24 revenue view to $601.5M-$604.5M from $594.5M-$604.5M
- Inari Medical reports Q3 EPS (31c), consensus (11c)
- NARI Earnings this Week: How Will it Perform?
- Inari Medical’s Artix 2.0 receives FDA approval, says BofA